OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 5.1 EUR -3.77%
Market Cap: 114.5m EUR

OSE Immunotherapeutics SA
Retained Earnings

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

OSE Immunotherapeutics SA
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Retained Earnings
-€31m
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
-18%
Valneva SE
PAR:VLA
Retained Earnings
-€548m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanobiotix SA
PAR:NANO
Retained Earnings
-€384m
CAGR 3-Years
-15%
CAGR 5-Years
-17%
CAGR 10-Years
-30%
Inventiva SA
PAR:IVA
Retained Earnings
-€387m
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Retained Earnings
-$139m
CAGR 3-Years
-48%
CAGR 5-Years
27%
CAGR 10-Years
-8%
Abivax SA
PAR:ABVX
Retained Earnings
-€529m
CAGR 3-Years
-70%
CAGR 5-Years
-103%
CAGR 10-Years
N/A
No Stocks Found

OSE Immunotherapeutics SA
Glance View

Market Cap
112.2m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
Not Available

See Also

What is OSE Immunotherapeutics SA's Retained Earnings?
Retained Earnings
-31m EUR

Based on the financial report for Jun 30, 2025, OSE Immunotherapeutics SA's Retained Earnings amounts to -31m EUR.

What is OSE Immunotherapeutics SA's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
-18%

The average annual Retained Earnings growth rates for OSE Immunotherapeutics SA have been -12% over the past three years , and -18% over the past ten years .

Back to Top